Épisodes

  • GLP-1 Drugs and Kidney Disease - Who Benefits Most and What Comes Next

    GLP-1 Drugs and Kidney Disease - Who Benefits Most and What Comes Next
    Apr 7 2026
    Join host Julia Cartwright as she explores who benefits most from GLP-1 receptor agonists in kidney disease treatment. From the groundbreaking FLOW trial results in diabetic patients to emerging research in non-diabetic kidney disease, discover what four pillars of modern kidney care mean for patients facing declining function, and what cutting-edge biopsy studies reveal about these medications' future potential.

    Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV

    This content was created in partnership and with the help of Artificial Intelligence AI
    Afficher plus Afficher moins
    22 min
  • GLP-1 Drugs and Kidney Disease - Inside the Kidney: How These Drugs Actually Work

    GLP-1 Drugs and Kidney Disease - Inside the Kidney: How These Drugs Actually Work
    Apr 7 2026
    Julia Cartwright explores how GLP-1 drugs protect kidneys through multiple pathways—reducing inflammation, scarring, and protein leakage while improving blood sugar and blood pressure. Research shows these medications lower kidney failure risk by 16% in diabetic and non-diabetic patients, offering hope beyond traditional treatments as a promising fourth pillar of kidney disease prevention.

    Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV

    This content was created in partnership and with the help of Artificial Intelligence AI
    Afficher plus Afficher moins
    29 min
  • GLP-1 Drugs and Kidney Disease - The Trial That Changed Everything

    GLP-1 Drugs and Kidney Disease - The Trial That Changed Everything
    Apr 7 2026
    Julia Cartwright explores how the FLOW trial revealed GLP-1 drugs like semaglutide offer groundbreaking kidney protection for diabetic patients, reducing kidney failure risk by 24%—results so powerful the study stopped early, establishing a fourth pillar in chronic kidney disease treatment alongside existing therapies.

    Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV

    This content was created in partnership and with the help of Artificial Intelligence AI
    Afficher plus Afficher moins
    24 min